Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen, Rubicon Genomics

Premium

Nanogen has finished beta-testing its ASRs for mutations in the CFTR gene and has begun a controlled launch of the products, which are associated with cystic fibrosis.

Nanogen also released a 3-SNP ASR for mutations in the HFE gene, which are associated with hereditary hemachromatosis. The firm also began beta-testing its Assay Tool Box product, which is expected to roll out by the end of the month.

Two other products began beta-testing, according to Nanogen: a test for beta-thalassemia and a multiplex ASR for Factor V and Factor II.

Lastly, the company said it is internally validating a protocol for Canavan disease and expects in March to begin beta-testing an ASR for apolipoprotein E, a genetic marker linked to Alzheimer’s.


Rubicon Genomics has unveiled its service business, which is based on its OmniPlex technology. Rubicon said the technology “restores large amounts of genetic information from very small amounts of degraded DNA.

Filed under

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.